Vaxil BioTherapeutics Utilizes Its Vaxhit Technology To Develop Superior Anti-MUC1 Antibodies
1/21/2014 9:25:24 AM
Ness Ziona, 21th January 2014. Vaxil Bio (TASE: VAXL), which is developing therapeutic vaccines to
treat cancer and infectious diseases, reports today that it has now demonstrated a major new major
application for its VaxHit technology. Using VaxHit, Vaxil can isolate signal peptide (SP) epitopes that
can be used as antigens for generating more specific antibodies against known and novel targets
including the MUC1 tumor marker. These are the first isolated, tumor specific, anti-SP antibodies
and their development is based on the unpredicted finding of tumor- associated, cell surface
existence of SP epitopes. Other anti-MUC1 antibodies in clinical development are directed against
epitopes in MUC1’s extracellular domain which appears on tumor cells but also on patient’s blood
thereby having reduced specificity and therapeutic potential. On the contrary, Vaxil’s mAb2.1 and
SPmAb-6 anti-MUC1 SP antibodies are targeting only MUC1-expressing tumor cells.
An article, (link attached), discussing Vaxil's discovery and development of the anti-MUC1 signal
peptide antibodies including their potential therapeutic role, was recently published in January
2014 in the Scientific Journal, PLos one.
An abstract summarizing these findings will also be presented later on this year at the American
association for cancer research (AACR) conference.
Dr. Lior Carmon Vaxil's CEO: "This new finding positions Vaxil’s products in the huge established
market for therapeutic antibodies, with a great unmet medical need, at least in the case of current
anti-MUC1 antibodies. Furthermore, the observations reported in the PLos-One article,
demonstrated that SPmAb2.1 and SPmAb-6 can also be used as a companion diagnostic to improve
patient selection for clinical trials using ImMucin and therefore potential success”.
Help employers find you! Check out all the jobs and post your resume.
comments powered by